161 related articles for article (PubMed ID: 1722139)
1. Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.
Avila-Cariño J; Torsteinsdottir S; Ehlin-Henriksson B; Masucci MG; Klein E
Cancer Immunol Immunother; 1991; 34(2):128-32. PubMed ID: 1722139
[TBL] [Abstract][Full Text] [Related]
2. Low expression of lymphocyte function-associated antigen (LFA)-1 and LFA-3 adhesion molecules is a common trait in Burkitt's lymphoma associated with and not associated with Epstein-Barr virus.
Billaud M; Rousset F; Calender A; Cordier M; Aubry JP; Laisse V; Lenoir GM
Blood; 1990 May; 75(9):1827-33. PubMed ID: 1691936
[TBL] [Abstract][Full Text] [Related]
3. Restoration of the LFA-3 adhesion pathway in Burkitt's lymphoma cells using an LFA-3 recombinant vaccinia virus: consequences for T cell recognition.
Griffin H; Rowe M; Murray R; Brooks J; Rickinson A
Eur J Immunol; 1992 Jul; 22(7):1741-8. PubMed ID: 1378014
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
Gregory CD; Murray RJ; Edwards CF; Rickinson AB
J Exp Med; 1988 Jun; 167(6):1811-24. PubMed ID: 2898508
[TBL] [Abstract][Full Text] [Related]
5. Target lysis by human LAK cells is critically dependent upon target binding properties, but LFA-1, LFA-3 and ICAM-1 are not the major adhesion ligands on targets.
Quillet-Mary A; Cavarec L; Kermarrec N; Marchiol-Fournigault C; Gil ML; Conjeaud H; Fradelizi D
Int J Cancer; 1991 Feb; 47(3):473-9. PubMed ID: 1704356
[TBL] [Abstract][Full Text] [Related]
6. Selective induction of allostimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines.
Cuomo L; Trivedi P; de Campos-Lima PO; Zhang QJ; Ragnar E; Klein G; Masucci MG
Mol Immunol; 1993 Apr; 30(5):441-50. PubMed ID: 7681932
[TBL] [Abstract][Full Text] [Related]
7. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
[TBL] [Abstract][Full Text] [Related]
9. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
Khanna R; Burrows SR; Suhrbier A; Jacob CA; Griffin H; Misko IS; Sculley TB; Rowe M; Rickinson AB; Moss DJ
J Immunol; 1993 Jun; 150(11):5154-62. PubMed ID: 7684421
[TBL] [Abstract][Full Text] [Related]
10. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
Torsteinsdottir S; Masucci MG; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5620-4. PubMed ID: 3016710
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV).
Calender A; Cordier M; Billaud M; Lenoir GM
Int J Cancer; 1990 Oct; 46(4):658-63. PubMed ID: 1698730
[TBL] [Abstract][Full Text] [Related]
12. Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures.
Cuomo L; Trivedi P; Wang F; Winberg G; Klein G; Masucci MG
Eur J Immunol; 1990 Oct; 20(10):2293-9. PubMed ID: 2173662
[TBL] [Abstract][Full Text] [Related]
13. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
Gregory CD; Rowe M; Rickinson AB
J Gen Virol; 1990 Jul; 71 ( Pt 7)():1481-95. PubMed ID: 2165133
[TBL] [Abstract][Full Text] [Related]
14. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
Torsteinsdottir S; Cuomo L; Klein E; Masucci MG
Cell Immunol; 1991 Oct; 137(2):501-13. PubMed ID: 1654213
[TBL] [Abstract][Full Text] [Related]
15. Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
Misko IS; Schmidt C; Martin N; Moss DJ; Sculley TB; Burrows S; Burman KJ
Int J Cancer; 1990 Sep; 46(3):399-404. PubMed ID: 2168343
[TBL] [Abstract][Full Text] [Related]
16. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cell sensitivity of human lymphoid lines of B-cell origin does not correlate with tumorigenicity or with the expression of certain differentiation markers.
Torsteinsdottir S; Masucci MG; Lenoir G; Klein G; Klein E
Cell Immunol; 1984 Jul; 86(2):278-86. PubMed ID: 6329520
[TBL] [Abstract][Full Text] [Related]
18. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype.
Falk MH; Trauth BC; Debatin KM; Klas C; Gregory CD; Rickinson AB; Calender A; Lenoir GM; Ellwart JW; Krammer PH
Blood; 1992 Jun; 79(12):3300-6. PubMed ID: 1375849
[TBL] [Abstract][Full Text] [Related]
19. Diploid human lymphoblastoid and Burkitt lymphoma cell lines: susceptibility to murine NK cells and heterotransplantation to nude mice.
McCormick KH; Giovanella BC; Klein G; Nilsson K; Stehlin JS
Int J Cancer; 1981 Oct; 28(4):455-8. PubMed ID: 6273332
[TBL] [Abstract][Full Text] [Related]
20. Both LFA-1-positive and -deficient T cell clones require the CD2/LFA-3 interaction for specific cytolytic activation.
Van de Wiel-van Kemenade E; Te Velde AA; De Boer AJ; Weening RS; Fischer A; Borst J; Melief CJ; Figdor CG
Eur J Immunol; 1992 Jun; 22(6):1467-75. PubMed ID: 1376259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
